Cencora, Inc. (LON:0HF3)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 52.63B |
| Revenue (ttm) | 239.05B |
| Net Income (ttm) | 1.16B |
| Shares Out | n/a |
| EPS (ttm) | 5.92 |
| PE Ratio | 45.52 |
| Forward PE | 20.20 |
| Dividend | 1.69 (0.48%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 876 |
| Average Volume | 501 |
| Open | 337.99 |
| Previous Close | 345.76 |
| Day's Range | 337.99 - 360.97 |
| 52-Week Range | 224.10 - 351.18 |
| Beta | 0.63 |
| RSI | 76.40 |
| Earnings Date | Nov 5, 2025 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply ... [Read more]
Financial Performance
In 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina ...
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Those looking to buy stocks right now should look for the ones that aren't correlated to the artificial intelligence trade.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the op...
Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Cencora, Inc. (NYSE:COR) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Hea...
Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript
Cencora, Inc. (NYSE:COR) Baird Global Healthcare Conference 2025 September 9, 2025 3:45 PM EDT Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury James Cleary - Ex...
Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Cencora, Inc. (NYSE:COR) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:45 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of In...
Cencora Appoints Mark Durcan as Chairman of Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, ...
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x for...
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and...
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
Cencora raises annual profit forecast on strong demand for specialty drugs
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl...
Cencora Reports Fiscal 2025 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On...
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the openi...
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerk...
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can d...
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in ...
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S...
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - Preside...
Cencora raises annual profit forecast on strong demand for specialty drugs
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.
Cencora Reports Fiscal 2025 Second Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion....
3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock
The S&P 500's three top performers in 2025 boast characteristics that could help them weather a further sell off.
These 15 stocks are the most profitable companies in the S&P 500
Keeping it simple is a good idea when it comes to investing in high-quality, defensive value stocks — especially now.
Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening...
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ cred...
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...